English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Although there is a widely used and highly effective attenuated live vaccine to combat yellow fever, there are very rare cases of serious adverse events associated with the vaccine. Therefore, in collaboration with Fraunhofer USA (FhCMB), Bio-Manguinhos / Fiocruz, is developing a plant-derived subunit vaccine for prevention of yellow fever. The vaccine candidate, termed YFE-1T, is based on the envelope protein (YFE) from Yellow fever virus strain 17DD. The vaccine candidate is produced in Nicotiana benthamiana plants, purified, characterized in vitro and in vivo. FhCMB utilizes transient expression technology based on an Agrobacterium tumefaciens type vector to rapidly produce high levels of YFE target protein in hydroponically grown fresh leaf biomass. We believe that the use of plants could provide a safer supply of proteins than natural or animal-based sources and may contribute a cost advantage over traditional bioreactor technology.

Yellow fever vaccine, recombinant envelope protein (rYFE), plant derived, for active immunization: pre-clinical studies in mice and monkey models